nodes	percent_of_prediction	percent_of_DWPC	metapath
Meloxicam—PGD—Dacarbazine—muscle cancer	0.352	0.609	CbGbCtD
Meloxicam—PTGS2—muscle cancer	0.337	1	CbGaD
Meloxicam—PGD—Methotrexate—muscle cancer	0.114	0.197	CbGbCtD
Meloxicam—ABCC4—Methotrexate—muscle cancer	0.0314	0.0544	CbGbCtD
Meloxicam—PTGS2—Etoposide—muscle cancer	0.0279	0.0484	CbGbCtD
Meloxicam—PTGS1—Etoposide—muscle cancer	0.0236	0.0408	CbGbCtD
Meloxicam—CYP2C8—Etoposide—muscle cancer	0.0136	0.0236	CbGbCtD
Meloxicam—CYP3A4—Vincristine—muscle cancer	0.00603	0.0104	CbGbCtD
Meloxicam—CYP3A4—Etoposide—muscle cancer	0.00552	0.00956	CbGbCtD
Meloxicam—CYP3A4—Doxorubicin—muscle cancer	0.00377	0.00652	CbGbCtD
Meloxicam—Lornoxicam—PTGS2—muscle cancer	0.00135	0.41	CrCbGaD
Meloxicam—Tenoxicam—PTGS2—muscle cancer	0.00121	0.365	CrCbGaD
Meloxicam—PTGS2—hindlimb—muscle cancer	0.000991	0.0967	CbGeAlD
Meloxicam—PTGS2—appendage—muscle cancer	0.00085	0.0829	CbGeAlD
Meloxicam—Piroxicam—PTGS2—muscle cancer	0.000746	0.225	CrCbGaD
Meloxicam—PGD—smooth muscle tissue—muscle cancer	0.000555	0.0541	CbGeAlD
Meloxicam—PGD—renal system—muscle cancer	0.000534	0.0521	CbGeAlD
Meloxicam—PGD—cardiac atrium—muscle cancer	0.000478	0.0466	CbGeAlD
Meloxicam—PGD—tendon—muscle cancer	0.000417	0.0406	CbGeAlD
Meloxicam—PGD—bone marrow—muscle cancer	0.000404	0.0394	CbGeAlD
Meloxicam—PGD—vagina—muscle cancer	0.000387	0.0377	CbGeAlD
Meloxicam—ABCC4—renal system—muscle cancer	0.00038	0.037	CbGeAlD
Meloxicam—PGD—head—muscle cancer	0.000357	0.0348	CbGeAlD
Meloxicam—PGD—testis—muscle cancer	0.000345	0.0337	CbGeAlD
Meloxicam—ABCC4—tendon—muscle cancer	0.000296	0.0289	CbGeAlD
Meloxicam—ABCC4—bone marrow—muscle cancer	0.000287	0.028	CbGeAlD
Meloxicam—PTGS2—embryo—muscle cancer	0.000282	0.0275	CbGeAlD
Meloxicam—CYP2C8—renal system—muscle cancer	0.000276	0.0269	CbGeAlD
Meloxicam—ABCC4—head—muscle cancer	0.000254	0.0248	CbGeAlD
Meloxicam—ABCC4—testis—muscle cancer	0.000245	0.0239	CbGeAlD
Meloxicam—PTGS1—smooth muscle tissue—muscle cancer	0.000232	0.0227	CbGeAlD
Meloxicam—PTGS1—renal system—muscle cancer	0.000224	0.0218	CbGeAlD
Meloxicam—PTGS2—smooth muscle tissue—muscle cancer	0.000222	0.0217	CbGeAlD
Meloxicam—PTGS2—renal system—muscle cancer	0.000214	0.0208	CbGeAlD
Meloxicam—PTGS1—cardiac atrium—muscle cancer	0.0002	0.0195	CbGeAlD
Meloxicam—CYP2C8—vagina—muscle cancer	0.0002	0.0195	CbGeAlD
Meloxicam—CYP3A4—renal system—muscle cancer	0.000187	0.0182	CbGeAlD
Meloxicam—CYP2C8—testis—muscle cancer	0.000178	0.0174	CbGeAlD
Meloxicam—PTGS1—tendon—muscle cancer	0.000175	0.017	CbGeAlD
Meloxicam—PTGS2—tendon—muscle cancer	0.000167	0.0163	CbGeAlD
Meloxicam—PTGS1—vagina—muscle cancer	0.000162	0.0158	CbGeAlD
Meloxicam—PTGS2—bone marrow—muscle cancer	0.000162	0.0158	CbGeAlD
Meloxicam—PTGS2—vagina—muscle cancer	0.000155	0.0151	CbGeAlD
Meloxicam—PTGS1—head—muscle cancer	0.00015	0.0146	CbGeAlD
Meloxicam—PTGS1—testis—muscle cancer	0.000144	0.0141	CbGeAlD
Meloxicam—PTGS2—head—muscle cancer	0.000143	0.0139	CbGeAlD
Meloxicam—Discomfort—Etoposide—muscle cancer	0.000143	0.00198	CcSEcCtD
Meloxicam—Face oedema—Doxorubicin—muscle cancer	0.000141	0.00196	CcSEcCtD
Meloxicam—Hypersensitivity—Dactinomycin—muscle cancer	0.000141	0.00196	CcSEcCtD
Meloxicam—Abdominal discomfort—Methotrexate—muscle cancer	0.00014	0.00194	CcSEcCtD
Meloxicam—Gastrointestinal pain—Vincristine—muscle cancer	0.00014	0.00194	CcSEcCtD
Meloxicam—Confusional state—Etoposide—muscle cancer	0.000139	0.00194	CcSEcCtD
Meloxicam—Pancytopenia—Methotrexate—muscle cancer	0.000138	0.00192	CcSEcCtD
Meloxicam—Anaphylactic shock—Etoposide—muscle cancer	0.000138	0.00192	CcSEcCtD
Meloxicam—Mood swings—Doxorubicin—muscle cancer	0.000138	0.00192	CcSEcCtD
Meloxicam—Infection—Etoposide—muscle cancer	0.000137	0.00191	CcSEcCtD
Meloxicam—Asthenia—Dactinomycin—muscle cancer	0.000137	0.00191	CcSEcCtD
Meloxicam—Blood creatinine increased—Doxorubicin—muscle cancer	0.000137	0.0019	CcSEcCtD
Meloxicam—Dehydration—Doxorubicin—muscle cancer	0.000136	0.00189	CcSEcCtD
Meloxicam—Thrombocytopenia—Etoposide—muscle cancer	0.000135	0.00188	CcSEcCtD
Meloxicam—Upper respiratory tract infection—Methotrexate—muscle cancer	0.000135	0.00188	CcSEcCtD
Meloxicam—Tachycardia—Etoposide—muscle cancer	0.000135	0.00188	CcSEcCtD
Meloxicam—Abdominal pain—Vincristine—muscle cancer	0.000135	0.00188	CcSEcCtD
Meloxicam—Body temperature increased—Vincristine—muscle cancer	0.000135	0.00188	CcSEcCtD
Meloxicam—Liver function test abnormal—Doxorubicin—muscle cancer	0.000135	0.00187	CcSEcCtD
Meloxicam—Skin disorder—Etoposide—muscle cancer	0.000134	0.00187	CcSEcCtD
Meloxicam—Hyperhidrosis—Etoposide—muscle cancer	0.000134	0.00186	CcSEcCtD
Meloxicam—Abdominal pain upper—Doxorubicin—muscle cancer	0.000133	0.00185	CcSEcCtD
Meloxicam—Photosensitivity reaction—Methotrexate—muscle cancer	0.000133	0.00185	CcSEcCtD
Meloxicam—Toxic epidermal necrolysis—Doxorubicin—muscle cancer	0.000131	0.00183	CcSEcCtD
Meloxicam—Aspartate aminotransferase increased—Doxorubicin—muscle cancer	0.000131	0.00183	CcSEcCtD
Meloxicam—Diarrhoea—Dactinomycin—muscle cancer	0.000131	0.00182	CcSEcCtD
Meloxicam—Nasopharyngitis—Doxorubicin—muscle cancer	0.000131	0.00182	CcSEcCtD
Meloxicam—Infestation—Methotrexate—muscle cancer	0.00013	0.00181	CcSEcCtD
Meloxicam—Drowsiness—Methotrexate—muscle cancer	0.00013	0.00181	CcSEcCtD
Meloxicam—Infestation NOS—Methotrexate—muscle cancer	0.00013	0.00181	CcSEcCtD
Meloxicam—Hypotension—Etoposide—muscle cancer	0.000129	0.0018	CcSEcCtD
Meloxicam—Gastritis—Doxorubicin—muscle cancer	0.000129	0.0018	CcSEcCtD
Meloxicam—Stevens-Johnson syndrome—Methotrexate—muscle cancer	0.000129	0.00179	CcSEcCtD
Meloxicam—Alanine aminotransferase increased—Doxorubicin—muscle cancer	0.000129	0.00179	CcSEcCtD
Meloxicam—Renal failure—Methotrexate—muscle cancer	0.000128	0.00178	CcSEcCtD
Meloxicam—Stomatitis—Methotrexate—muscle cancer	0.000127	0.00176	CcSEcCtD
Meloxicam—Conjunctivitis—Methotrexate—muscle cancer	0.000126	0.00176	CcSEcCtD
Meloxicam—Influenza—Doxorubicin—muscle cancer	0.000126	0.00175	CcSEcCtD
Meloxicam—Asthma—Doxorubicin—muscle cancer	0.000126	0.00175	CcSEcCtD
Meloxicam—Hypersensitivity—Vincristine—muscle cancer	0.000126	0.00175	CcSEcCtD
Meloxicam—Sweating—Methotrexate—muscle cancer	0.000125	0.00173	CcSEcCtD
Meloxicam—Paraesthesia—Etoposide—muscle cancer	0.000124	0.00173	CcSEcCtD
Meloxicam—Haematuria—Methotrexate—muscle cancer	0.000124	0.00172	CcSEcCtD
Meloxicam—Pancreatitis—Doxorubicin—muscle cancer	0.000124	0.00172	CcSEcCtD
Meloxicam—Dyspnoea—Etoposide—muscle cancer	0.000123	0.00171	CcSEcCtD
Meloxicam—Somnolence—Etoposide—muscle cancer	0.000123	0.00171	CcSEcCtD
Meloxicam—Angina pectoris—Doxorubicin—muscle cancer	0.000123	0.00171	CcSEcCtD
Meloxicam—Hepatobiliary disease—Methotrexate—muscle cancer	0.000123	0.00171	CcSEcCtD
Meloxicam—Asthenia—Vincristine—muscle cancer	0.000122	0.0017	CcSEcCtD
Meloxicam—Vomiting—Dactinomycin—muscle cancer	0.000122	0.00169	CcSEcCtD
Meloxicam—Bronchitis—Doxorubicin—muscle cancer	0.000121	0.00169	CcSEcCtD
Meloxicam—Agranulocytosis—Methotrexate—muscle cancer	0.000121	0.00169	CcSEcCtD
Meloxicam—Rash—Dactinomycin—muscle cancer	0.00012	0.00168	CcSEcCtD
Meloxicam—Decreased appetite—Etoposide—muscle cancer	0.00012	0.00167	CcSEcCtD
Meloxicam—Pancytopenia—Doxorubicin—muscle cancer	0.00012	0.00167	CcSEcCtD
Meloxicam—Gastrointestinal disorder—Etoposide—muscle cancer	0.000119	0.00166	CcSEcCtD
Meloxicam—Fatigue—Etoposide—muscle cancer	0.000119	0.00166	CcSEcCtD
Meloxicam—Constipation—Etoposide—muscle cancer	0.000118	0.00164	CcSEcCtD
Meloxicam—Pain—Etoposide—muscle cancer	0.000118	0.00164	CcSEcCtD
Meloxicam—Upper respiratory tract infection—Doxorubicin—muscle cancer	0.000117	0.00163	CcSEcCtD
Meloxicam—Haemoglobin—Methotrexate—muscle cancer	0.000117	0.00163	CcSEcCtD
Meloxicam—Diarrhoea—Vincristine—muscle cancer	0.000117	0.00162	CcSEcCtD
Meloxicam—Haemorrhage—Methotrexate—muscle cancer	0.000117	0.00162	CcSEcCtD
Meloxicam—Hepatitis—Methotrexate—muscle cancer	0.000117	0.00162	CcSEcCtD
Meloxicam—Pollakiuria—Doxorubicin—muscle cancer	0.000117	0.00162	CcSEcCtD
Meloxicam—Pharyngitis—Methotrexate—muscle cancer	0.000116	0.00161	CcSEcCtD
Meloxicam—Urinary tract disorder—Methotrexate—muscle cancer	0.000115	0.0016	CcSEcCtD
Meloxicam—Photosensitivity reaction—Doxorubicin—muscle cancer	0.000115	0.0016	CcSEcCtD
Meloxicam—Weight increased—Doxorubicin—muscle cancer	0.000115	0.0016	CcSEcCtD
Meloxicam—Urethral disorder—Methotrexate—muscle cancer	0.000114	0.00159	CcSEcCtD
Meloxicam—Weight decreased—Doxorubicin—muscle cancer	0.000114	0.00159	CcSEcCtD
Meloxicam—Feeling abnormal—Etoposide—muscle cancer	0.000114	0.00159	CcSEcCtD
Meloxicam—Nausea—Dactinomycin—muscle cancer	0.000114	0.00158	CcSEcCtD
Meloxicam—Gastrointestinal pain—Etoposide—muscle cancer	0.000113	0.00157	CcSEcCtD
Meloxicam—Dizziness—Vincristine—muscle cancer	0.000113	0.00157	CcSEcCtD
Meloxicam—Infestation—Doxorubicin—muscle cancer	0.000112	0.00156	CcSEcCtD
Meloxicam—Drowsiness—Doxorubicin—muscle cancer	0.000112	0.00156	CcSEcCtD
Meloxicam—Infestation NOS—Doxorubicin—muscle cancer	0.000112	0.00156	CcSEcCtD
Meloxicam—Visual impairment—Methotrexate—muscle cancer	0.000112	0.00156	CcSEcCtD
Meloxicam—Stevens-Johnson syndrome—Doxorubicin—muscle cancer	0.000112	0.00155	CcSEcCtD
Meloxicam—Renal failure—Doxorubicin—muscle cancer	0.000111	0.00154	CcSEcCtD
Meloxicam—Erythema multiforme—Methotrexate—muscle cancer	0.00011	0.00153	CcSEcCtD
Meloxicam—Urticaria—Etoposide—muscle cancer	0.00011	0.00153	CcSEcCtD
Meloxicam—Stomatitis—Doxorubicin—muscle cancer	0.00011	0.00152	CcSEcCtD
Meloxicam—Jaundice—Doxorubicin—muscle cancer	0.00011	0.00152	CcSEcCtD
Meloxicam—Abdominal pain—Etoposide—muscle cancer	0.000109	0.00152	CcSEcCtD
Meloxicam—Body temperature increased—Etoposide—muscle cancer	0.000109	0.00152	CcSEcCtD
Meloxicam—Urinary tract infection—Doxorubicin—muscle cancer	0.000109	0.00152	CcSEcCtD
Meloxicam—Conjunctivitis—Doxorubicin—muscle cancer	0.000109	0.00152	CcSEcCtD
Meloxicam—Eye disorder—Methotrexate—muscle cancer	0.000109	0.00152	CcSEcCtD
Meloxicam—Tinnitus—Methotrexate—muscle cancer	0.000109	0.00151	CcSEcCtD
Meloxicam—Vomiting—Vincristine—muscle cancer	0.000109	0.00151	CcSEcCtD
Meloxicam—Cardiac disorder—Methotrexate—muscle cancer	0.000108	0.00151	CcSEcCtD
Meloxicam—Sweating—Doxorubicin—muscle cancer	0.000108	0.0015	CcSEcCtD
Meloxicam—Rash—Vincristine—muscle cancer	0.000108	0.0015	CcSEcCtD
Meloxicam—Dermatitis—Vincristine—muscle cancer	0.000108	0.0015	CcSEcCtD
Meloxicam—Haematuria—Doxorubicin—muscle cancer	0.000107	0.00149	CcSEcCtD
Meloxicam—Headache—Vincristine—muscle cancer	0.000107	0.00149	CcSEcCtD
Meloxicam—Hepatobiliary disease—Doxorubicin—muscle cancer	0.000106	0.00148	CcSEcCtD
Meloxicam—Angiopathy—Methotrexate—muscle cancer	0.000106	0.00147	CcSEcCtD
Meloxicam—Sinusitis—Doxorubicin—muscle cancer	0.000106	0.00147	CcSEcCtD
Meloxicam—Immune system disorder—Methotrexate—muscle cancer	0.000105	0.00146	CcSEcCtD
Meloxicam—Mediastinal disorder—Methotrexate—muscle cancer	0.000105	0.00146	CcSEcCtD
Meloxicam—Agranulocytosis—Doxorubicin—muscle cancer	0.000105	0.00146	CcSEcCtD
Meloxicam—Alopecia—Methotrexate—muscle cancer	0.000103	0.00143	CcSEcCtD
Meloxicam—Mental disorder—Methotrexate—muscle cancer	0.000102	0.00142	CcSEcCtD
Meloxicam—Hypersensitivity—Etoposide—muscle cancer	0.000102	0.00142	CcSEcCtD
Meloxicam—Malnutrition—Methotrexate—muscle cancer	0.000102	0.00141	CcSEcCtD
Meloxicam—Erythema—Methotrexate—muscle cancer	0.000102	0.00141	CcSEcCtD
Meloxicam—Haemoglobin—Doxorubicin—muscle cancer	0.000101	0.00141	CcSEcCtD
Meloxicam—Nausea—Vincristine—muscle cancer	0.000101	0.00141	CcSEcCtD
Meloxicam—Rhinitis—Doxorubicin—muscle cancer	0.000101	0.00141	CcSEcCtD
Meloxicam—Haemorrhage—Doxorubicin—muscle cancer	0.000101	0.0014	CcSEcCtD
Meloxicam—Hepatitis—Doxorubicin—muscle cancer	0.000101	0.0014	CcSEcCtD
Meloxicam—Pharyngitis—Doxorubicin—muscle cancer	0.0001	0.00139	CcSEcCtD
Meloxicam—Urinary tract disorder—Doxorubicin—muscle cancer	9.97e-05	0.00139	CcSEcCtD
Meloxicam—Oedema peripheral—Doxorubicin—muscle cancer	9.95e-05	0.00138	CcSEcCtD
Meloxicam—Dysgeusia—Methotrexate—muscle cancer	9.94e-05	0.00138	CcSEcCtD
Meloxicam—Asthenia—Etoposide—muscle cancer	9.92e-05	0.00138	CcSEcCtD
Meloxicam—Connective tissue disorder—Doxorubicin—muscle cancer	9.92e-05	0.00138	CcSEcCtD
Meloxicam—Urethral disorder—Doxorubicin—muscle cancer	9.9e-05	0.00138	CcSEcCtD
Meloxicam—Back pain—Methotrexate—muscle cancer	9.82e-05	0.00137	CcSEcCtD
Meloxicam—Pruritus—Etoposide—muscle cancer	9.79e-05	0.00136	CcSEcCtD
Meloxicam—Visual impairment—Doxorubicin—muscle cancer	9.73e-05	0.00135	CcSEcCtD
Meloxicam—Vision blurred—Methotrexate—muscle cancer	9.57e-05	0.00133	CcSEcCtD
Meloxicam—Erythema multiforme—Doxorubicin—muscle cancer	9.55e-05	0.00133	CcSEcCtD
Meloxicam—Diarrhoea—Etoposide—muscle cancer	9.46e-05	0.00132	CcSEcCtD
Meloxicam—Eye disorder—Doxorubicin—muscle cancer	9.44e-05	0.00131	CcSEcCtD
Meloxicam—Ill-defined disorder—Methotrexate—muscle cancer	9.42e-05	0.00131	CcSEcCtD
Meloxicam—Tinnitus—Doxorubicin—muscle cancer	9.41e-05	0.00131	CcSEcCtD
Meloxicam—Anaemia—Methotrexate—muscle cancer	9.38e-05	0.0013	CcSEcCtD
Meloxicam—Flushing—Doxorubicin—muscle cancer	9.37e-05	0.0013	CcSEcCtD
Meloxicam—Cardiac disorder—Doxorubicin—muscle cancer	9.37e-05	0.0013	CcSEcCtD
Meloxicam—Angiopathy—Doxorubicin—muscle cancer	9.16e-05	0.00127	CcSEcCtD
Meloxicam—Malaise—Methotrexate—muscle cancer	9.15e-05	0.00127	CcSEcCtD
Meloxicam—Dizziness—Etoposide—muscle cancer	9.15e-05	0.00127	CcSEcCtD
Meloxicam—Immune system disorder—Doxorubicin—muscle cancer	9.12e-05	0.00127	CcSEcCtD
Meloxicam—Vertigo—Methotrexate—muscle cancer	9.12e-05	0.00127	CcSEcCtD
Meloxicam—Mediastinal disorder—Doxorubicin—muscle cancer	9.1e-05	0.00127	CcSEcCtD
Meloxicam—Leukopenia—Methotrexate—muscle cancer	9.09e-05	0.00126	CcSEcCtD
Meloxicam—Arrhythmia—Doxorubicin—muscle cancer	9.02e-05	0.00125	CcSEcCtD
Meloxicam—Alopecia—Doxorubicin—muscle cancer	8.92e-05	0.00124	CcSEcCtD
Meloxicam—Cough—Methotrexate—muscle cancer	8.86e-05	0.00123	CcSEcCtD
Meloxicam—Mental disorder—Doxorubicin—muscle cancer	8.85e-05	0.00123	CcSEcCtD
Meloxicam—Convulsion—Methotrexate—muscle cancer	8.79e-05	0.00122	CcSEcCtD
Meloxicam—Vomiting—Etoposide—muscle cancer	8.79e-05	0.00122	CcSEcCtD
Meloxicam—Malnutrition—Doxorubicin—muscle cancer	8.79e-05	0.00122	CcSEcCtD
Meloxicam—Erythema—Doxorubicin—muscle cancer	8.79e-05	0.00122	CcSEcCtD
Meloxicam—Rash—Etoposide—muscle cancer	8.72e-05	0.00121	CcSEcCtD
Meloxicam—Dermatitis—Etoposide—muscle cancer	8.71e-05	0.00121	CcSEcCtD
Meloxicam—Headache—Etoposide—muscle cancer	8.66e-05	0.00121	CcSEcCtD
Meloxicam—Flatulence—Doxorubicin—muscle cancer	8.66e-05	0.0012	CcSEcCtD
Meloxicam—Myalgia—Methotrexate—muscle cancer	8.64e-05	0.0012	CcSEcCtD
Meloxicam—Arthralgia—Methotrexate—muscle cancer	8.64e-05	0.0012	CcSEcCtD
Meloxicam—Tension—Doxorubicin—muscle cancer	8.63e-05	0.0012	CcSEcCtD
Meloxicam—Dysgeusia—Doxorubicin—muscle cancer	8.61e-05	0.0012	CcSEcCtD
Meloxicam—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—muscle cancer	8.58e-05	0.00119	CcSEcCtD
Meloxicam—Discomfort—Methotrexate—muscle cancer	8.54e-05	0.00119	CcSEcCtD
Meloxicam—Nervousness—Doxorubicin—muscle cancer	8.54e-05	0.00119	CcSEcCtD
Meloxicam—Back pain—Doxorubicin—muscle cancer	8.5e-05	0.00118	CcSEcCtD
Meloxicam—Muscle spasms—Doxorubicin—muscle cancer	8.45e-05	0.00118	CcSEcCtD
Meloxicam—Confusional state—Methotrexate—muscle cancer	8.35e-05	0.00116	CcSEcCtD
Meloxicam—Anaphylactic shock—Methotrexate—muscle cancer	8.28e-05	0.00115	CcSEcCtD
Meloxicam—Vision blurred—Doxorubicin—muscle cancer	8.28e-05	0.00115	CcSEcCtD
Meloxicam—Infection—Methotrexate—muscle cancer	8.23e-05	0.00114	CcSEcCtD
Meloxicam—Nausea—Etoposide—muscle cancer	8.22e-05	0.00114	CcSEcCtD
Meloxicam—Ill-defined disorder—Doxorubicin—muscle cancer	8.16e-05	0.00113	CcSEcCtD
Meloxicam—Nervous system disorder—Methotrexate—muscle cancer	8.12e-05	0.00113	CcSEcCtD
Meloxicam—Anaemia—Doxorubicin—muscle cancer	8.12e-05	0.00113	CcSEcCtD
Meloxicam—Thrombocytopenia—Methotrexate—muscle cancer	8.11e-05	0.00113	CcSEcCtD
Meloxicam—Skin disorder—Methotrexate—muscle cancer	8.05e-05	0.00112	CcSEcCtD
Meloxicam—Hyperhidrosis—Methotrexate—muscle cancer	8.01e-05	0.00111	CcSEcCtD
Meloxicam—Malaise—Doxorubicin—muscle cancer	7.93e-05	0.0011	CcSEcCtD
Meloxicam—Vertigo—Doxorubicin—muscle cancer	7.9e-05	0.0011	CcSEcCtD
Meloxicam—Syncope—Doxorubicin—muscle cancer	7.88e-05	0.0011	CcSEcCtD
Meloxicam—Leukopenia—Doxorubicin—muscle cancer	7.87e-05	0.00109	CcSEcCtD
Meloxicam—Palpitations—Doxorubicin—muscle cancer	7.77e-05	0.00108	CcSEcCtD
Meloxicam—Hypotension—Methotrexate—muscle cancer	7.74e-05	0.00108	CcSEcCtD
Meloxicam—Loss of consciousness—Doxorubicin—muscle cancer	7.73e-05	0.00107	CcSEcCtD
Meloxicam—Cough—Doxorubicin—muscle cancer	7.67e-05	0.00107	CcSEcCtD
Meloxicam—Convulsion—Doxorubicin—muscle cancer	7.62e-05	0.00106	CcSEcCtD
Meloxicam—Hypertension—Doxorubicin—muscle cancer	7.59e-05	0.00106	CcSEcCtD
Meloxicam—Musculoskeletal discomfort—Methotrexate—muscle cancer	7.55e-05	0.00105	CcSEcCtD
Meloxicam—Insomnia—Methotrexate—muscle cancer	7.49e-05	0.00104	CcSEcCtD
Meloxicam—Arthralgia—Doxorubicin—muscle cancer	7.48e-05	0.00104	CcSEcCtD
Meloxicam—Myalgia—Doxorubicin—muscle cancer	7.48e-05	0.00104	CcSEcCtD
Meloxicam—Anxiety—Doxorubicin—muscle cancer	7.46e-05	0.00104	CcSEcCtD
Meloxicam—Paraesthesia—Methotrexate—muscle cancer	7.44e-05	0.00103	CcSEcCtD
Meloxicam—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—muscle cancer	7.43e-05	0.00103	CcSEcCtD
Meloxicam—Discomfort—Doxorubicin—muscle cancer	7.39e-05	0.00103	CcSEcCtD
Meloxicam—Dyspnoea—Methotrexate—muscle cancer	7.39e-05	0.00103	CcSEcCtD
Meloxicam—Somnolence—Methotrexate—muscle cancer	7.36e-05	0.00102	CcSEcCtD
Meloxicam—Dry mouth—Doxorubicin—muscle cancer	7.32e-05	0.00102	CcSEcCtD
Meloxicam—Dyspepsia—Methotrexate—muscle cancer	7.29e-05	0.00101	CcSEcCtD
Meloxicam—Confusional state—Doxorubicin—muscle cancer	7.23e-05	0.00101	CcSEcCtD
Meloxicam—Decreased appetite—Methotrexate—muscle cancer	7.2e-05	0.001	CcSEcCtD
Meloxicam—Oedema—Doxorubicin—muscle cancer	7.17e-05	0.000998	CcSEcCtD
Meloxicam—Anaphylactic shock—Doxorubicin—muscle cancer	7.17e-05	0.000998	CcSEcCtD
Meloxicam—Gastrointestinal disorder—Methotrexate—muscle cancer	7.15e-05	0.000995	CcSEcCtD
Meloxicam—Fatigue—Methotrexate—muscle cancer	7.14e-05	0.000993	CcSEcCtD
Meloxicam—Infection—Doxorubicin—muscle cancer	7.13e-05	0.000991	CcSEcCtD
Meloxicam—Pain—Methotrexate—muscle cancer	7.08e-05	0.000985	CcSEcCtD
Meloxicam—Shock—Doxorubicin—muscle cancer	7.06e-05	0.000982	CcSEcCtD
Meloxicam—Nervous system disorder—Doxorubicin—muscle cancer	7.03e-05	0.000978	CcSEcCtD
Meloxicam—Thrombocytopenia—Doxorubicin—muscle cancer	7.02e-05	0.000977	CcSEcCtD
Meloxicam—Tachycardia—Doxorubicin—muscle cancer	7e-05	0.000974	CcSEcCtD
Meloxicam—Skin disorder—Doxorubicin—muscle cancer	6.97e-05	0.000969	CcSEcCtD
Meloxicam—Hyperhidrosis—Doxorubicin—muscle cancer	6.93e-05	0.000964	CcSEcCtD
Meloxicam—Feeling abnormal—Methotrexate—muscle cancer	6.83e-05	0.000949	CcSEcCtD
Meloxicam—Gastrointestinal pain—Methotrexate—muscle cancer	6.77e-05	0.000942	CcSEcCtD
Meloxicam—Hypotension—Doxorubicin—muscle cancer	6.7e-05	0.000932	CcSEcCtD
Meloxicam—Urticaria—Methotrexate—muscle cancer	6.58e-05	0.000915	CcSEcCtD
Meloxicam—Abdominal pain—Methotrexate—muscle cancer	6.55e-05	0.000911	CcSEcCtD
Meloxicam—Body temperature increased—Methotrexate—muscle cancer	6.55e-05	0.000911	CcSEcCtD
Meloxicam—Musculoskeletal discomfort—Doxorubicin—muscle cancer	6.54e-05	0.000909	CcSEcCtD
Meloxicam—Insomnia—Doxorubicin—muscle cancer	6.49e-05	0.000902	CcSEcCtD
Meloxicam—Paraesthesia—Doxorubicin—muscle cancer	6.44e-05	0.000896	CcSEcCtD
Meloxicam—Dyspnoea—Doxorubicin—muscle cancer	6.4e-05	0.000889	CcSEcCtD
Meloxicam—Somnolence—Doxorubicin—muscle cancer	6.38e-05	0.000887	CcSEcCtD
Meloxicam—Dyspepsia—Doxorubicin—muscle cancer	6.31e-05	0.000878	CcSEcCtD
Meloxicam—Decreased appetite—Doxorubicin—muscle cancer	6.24e-05	0.000867	CcSEcCtD
Meloxicam—Gastrointestinal disorder—Doxorubicin—muscle cancer	6.19e-05	0.000861	CcSEcCtD
Meloxicam—Fatigue—Doxorubicin—muscle cancer	6.18e-05	0.00086	CcSEcCtD
Meloxicam—Pain—Doxorubicin—muscle cancer	6.13e-05	0.000853	CcSEcCtD
Meloxicam—Constipation—Doxorubicin—muscle cancer	6.13e-05	0.000853	CcSEcCtD
Meloxicam—Hypersensitivity—Methotrexate—muscle cancer	6.1e-05	0.000849	CcSEcCtD
Meloxicam—Asthenia—Methotrexate—muscle cancer	5.94e-05	0.000827	CcSEcCtD
Meloxicam—Feeling abnormal—Doxorubicin—muscle cancer	5.91e-05	0.000822	CcSEcCtD
Meloxicam—Gastrointestinal pain—Doxorubicin—muscle cancer	5.87e-05	0.000816	CcSEcCtD
Meloxicam—Pruritus—Methotrexate—muscle cancer	5.86e-05	0.000815	CcSEcCtD
Meloxicam—Urticaria—Doxorubicin—muscle cancer	5.7e-05	0.000793	CcSEcCtD
Meloxicam—Body temperature increased—Doxorubicin—muscle cancer	5.67e-05	0.000789	CcSEcCtD
Meloxicam—Abdominal pain—Doxorubicin—muscle cancer	5.67e-05	0.000789	CcSEcCtD
Meloxicam—Diarrhoea—Methotrexate—muscle cancer	5.67e-05	0.000788	CcSEcCtD
Meloxicam—Dizziness—Methotrexate—muscle cancer	5.48e-05	0.000762	CcSEcCtD
Meloxicam—Hypersensitivity—Doxorubicin—muscle cancer	5.29e-05	0.000735	CcSEcCtD
Meloxicam—Vomiting—Methotrexate—muscle cancer	5.27e-05	0.000733	CcSEcCtD
Meloxicam—Rash—Methotrexate—muscle cancer	5.22e-05	0.000726	CcSEcCtD
Meloxicam—Dermatitis—Methotrexate—muscle cancer	5.22e-05	0.000726	CcSEcCtD
Meloxicam—Headache—Methotrexate—muscle cancer	5.19e-05	0.000722	CcSEcCtD
Meloxicam—Asthenia—Doxorubicin—muscle cancer	5.15e-05	0.000716	CcSEcCtD
Meloxicam—Pruritus—Doxorubicin—muscle cancer	5.08e-05	0.000706	CcSEcCtD
Meloxicam—Nausea—Methotrexate—muscle cancer	4.92e-05	0.000684	CcSEcCtD
Meloxicam—Diarrhoea—Doxorubicin—muscle cancer	4.91e-05	0.000683	CcSEcCtD
Meloxicam—Dizziness—Doxorubicin—muscle cancer	4.74e-05	0.00066	CcSEcCtD
Meloxicam—Vomiting—Doxorubicin—muscle cancer	4.56e-05	0.000634	CcSEcCtD
Meloxicam—Rash—Doxorubicin—muscle cancer	4.52e-05	0.000629	CcSEcCtD
Meloxicam—Dermatitis—Doxorubicin—muscle cancer	4.52e-05	0.000628	CcSEcCtD
Meloxicam—Headache—Doxorubicin—muscle cancer	4.49e-05	0.000625	CcSEcCtD
Meloxicam—Nausea—Doxorubicin—muscle cancer	4.26e-05	0.000593	CcSEcCtD
